Skip to content

Pulmatrix Inc Sustainability Reports

Pulmatrix, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative inhaled therapies for respiratory and non-pulmonary diseases. The company utilizes its patented iSPERSE dry powder delivery platform to maximize therapeutic efficiency locally while minimizing systemic side effects.

Sector: Manufacturing

Country: United States

Exchange: Nasdaq

LEI: 5299002RHCRZ9ST3GN42

FIGI: BBG003TH2QM0

3 reports from 2019 to 2021